Skip to main content
EyePoint Pharmaceuticals, Inc. logo

EyePoint Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · EYPT ISIN · US74440J1016 LEI · 549300QE1RU34T50MR69 US Manufacturing
Open in API
Filings indexed 1,019 across all filing types
Latest filing 2008-06-27 Director's Dealing
Country US United States of America
Listing US EYPT

About EyePoint Pharmaceuticals, Inc.

https://eyepointpharma.com/

EyePoint Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for serious retinal diseases. The company leverages its proprietary Durasert E™ technology, a bio-erodible platform for sustained intraocular drug delivery, to create durable therapies. Its lead investigational product, DURAVYU™ (EYP-1901), combines the tyrosine kinase inhibitor vorolanib with the Durasert E™ system for the potential treatment of VEGF-mediated retinal diseases. The company's goal is to improve patient outcomes and reduce treatment burden by providing long-lasting treatments for chronic eye conditions.

Recent filings

Filing Released Lang Actions
FORM 3
Director's Dealing
2008-06-27 English
FORM 3
Director's Dealing
2008-06-27 English
FORM 3
Director's Dealing
2008-06-27 English
FORM 3
Director's Dealing
2008-06-27 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes a corporate restructuring event where pSivida Limited reincorporated from Australia to the United States through a scheme of arrangement, involving share exchanges and asset transfers. This is a specific event announcement related to capital structure and corporate reorganization. The document is relatively short (3,584 characters) and does not contain detailed financial statements or comprehensive financial analysis. It is not an annual or quarterly report, nor an earnings release or management discussion. The primary focus is on the issuance of shares pursuant to the scheme and the legal and regulatory aspects of the reincorporation. This fits best under Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. Therefore, the correct classification is CAP with high confidence.
2008-06-24 English
POST EFFECTIVE AMENDMENT NO. 1 TO FORMS F-3 ON FORM S-3
Capital/Financing Update Classification · 95% confidence The document is titled 'Post Effective Amendment No. 1 to Forms F-3 on Form S-3' and is a registration statement filed with the SEC under the Securities Act of 1933. It relates to the registration of securities, specifically common stock underlying warrants, and includes detailed information about the company, the securities being registered, and the terms of the offering. The document is a regulatory filing related to securities registration and amendments to registration statements, not a financial report, earnings release, or other types of filings. It is a post-effective amendment to registration statements, which is a type of capital/financing update or regulatory filing. Given the nature of the document as a post-effective amendment to registration statements and the detailed registration information, the most appropriate classification is Capital/Financing Update (CAP). The document is lengthy (15,000 characters) and contains substantive content, not merely an announcement or certification, so it is not RPA or RNS. Therefore, the filing type code is CAP with high confidence.
2008-06-19 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.